Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants

• Autoři: TROTMAN Judith; FOURNIER Marion; LAMY Thierry; SEYMOUR John Francis; SONET Anne; JANÍKOVÁ Andrea; SHPILBERG Ofer; GYAN Emmanuel; TILLY Hervé; ESTELL Jane; FORSYTH Cecily; DECAUDIN Didier; FABIANI Bettina; GABARRE Jean; SALLES Bruno; VAN DEN NESTE Eric; CANIONI Danielle; GARIN Etienne; FULHAM Michael; VANDER BORGHT Thierry; SALLES Gilles
• Rok publikování: 2011
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Journal of Clinical Oncology
• Fakulta / Pracoviště MU: Lékařská fakulta
• Doi: http://dx.doi.org/10.1200/JCO.2011.35.0736
• Obor: Onkologie a hematologie
• Klíčová slova: INTERNATIONAL PROGNOSTIC INDEX; NON-HODGKINS-LYMPHOMA; RESPONSE CRITERIA; FOLLOW-UP; FDG-PET; MANAGEMENT; IMPACT; RITUXIMAB; F-18-FDG; SURVIVAL
• Popis: The utility of [18F]fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET-CT) in assessing response at the end of induction therapy is well documented in Hodgkin's and diffuse large B-cell lymphomas, but its role in follicular lymphoma (FL) remains undetermined. We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study. Results of PET-CT scans performed after induction immunochemotherapy were recorded retrospectively. Patients went on to either observation or rituximab maintenance per protocol independent of the PET-CT result. Patient characteristics and outcomes were then evaluated. Of 122 PET-CT scans performed at the end of the induction immunochemotherapy, 32 (26%) were reported as positive by the local investigator. Initial demographic or disease characteristics did not differ between PET-CT–positive (PET-positive) and PET-CT–negative (PET-negative) patients. PET status correlated with conventional response criteria (P < .001). Patients remaining PET positive had a significantly (P < .001) inferior progression-free survival at 42 months of 32.9% (95% CI, 17.2% to 49.5%) compared with 70.7% (95% CI, 59.3% to 79.4%) in those who became PET negative. PET status, but not conventional response (complete response or complete response unconfirmed v partial response) according to IWC 1999, was an independent predictive factor for lymphoma progression. The risk of death was also increased in PET-positive patients (hazard ratio 7.0; P = .0011). [18F]FDG PET-CT status at the end of immunochemotherapy induction in patients with FL is strongly predictive of outcome and should be considered a meaningful clinical end point in future studies.